Fusion Pharmaceuticals Announces First Quarter 2021 Financial Results and Business Update
News provided by
Share this article
Continuing expansion of pipeline of targeted alpha therapies through recently completed transactions
HAMILTON, ON and BOSTON, May 11, 2021 /PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced financial results for the first quarter ended March 31, 2021 and provided an update on clinical and corporate developments. We continue to advance our Phase 1 study of FPI-1434, said Chief Executive Officer John Valliant, Ph.D. In anticipation of data and determination of a recommended Phase 2 dose in the first half of 2022, we are amending the study protocol to define tumor-specific cohorts based upon IGF-1R expression and tumor uptake as seen to date in the Phase 1 study.
Fusion Pharmaceuticals Announces Preclinical Combination Data Demonstrating Enhanced Efficacy in Multiple Preclinical Tumor Models
News provided by
Share this article
Share this article
Product candidate FPI-1434, when administered with olaparib, resulted in enhanced efficacy against colorectal and lung cancer xenografts
Combination of IGF-1R targeted alpha therapy with immune checkpoint inhibitors demonstrated enhanced efficacy in colorectal cancer models
Data featured in e-poster sessions at the 2021 AACR Virtual Annual Meeting
HAMILTON, ON and BOSTON, April 10, 2021 /PRNewswire/ Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced the presentation of preclinical data at the 2021 American Association for Cancer Research (AACR) Virtual Annual Meeting. The posters will be presented during the Preclinical Radiotherapeutics and Combination Immunotherap